- Preliminary efficacy results in Phase 1/2 trial of mifepristone plus eribulin (Eisai’s Halaven®) to treat triple-negative breast cancer (TNBC) indicate combination is active; final results expected in mid-2016
- First patient enrolled in Phase 1/2 trial of selective cortisol modulator CORT125134 plus nab-paclitaxel (Celgene’s Abraxane®) to treat a range of solid-tumor cancers
- First patient enrolled in University of Chicago Phase 2 trial of mifepristone plus enzalutamide (Medivation’s Xtandi®) to treat metastatic, castration-resistant prostate cancer (CRPC)
- The University of Chicago to conduct a Phase 2 trial, supported by Celgene Corporation and Corcept Therapeutics, of mifepristone plus Abraxane to treat patients with TNBC
Catalyst
Slingshot members are tracking this event:
Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CORT | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 02, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Mifepristone, Eribulin, Halaven, Abraxane, Nab-paclitaxel, Cort125134, Cortisol, Castration-resistant Prostate Cancer, Xtandi
